Physician profile
Emma Stolyar
NPI 1457399008
$3,153.64
in general payments reported to CMS, 2019-2025
23 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $510 · 2021: $746 · 2022: $386 · 2023: $234 · 2024: $265 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $656.85 | 2019-2025 | Creon, Ubrelvy |
| Kowa Pharmaceuticals America, INC. | $498.60 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $463.99 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $363.88 | 2019-2022 | |
| Horizon Therapeutics Plc | $242.27 | 2019-2022 | |
| Novo Nordisk INC | $141.93 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $110.05 | 2021-2024 | Farxiga |
| Amgen INC. | $99.49 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $77.49 | 2019-2021 | |
| Glaxosmithkline, LLC. | $64.48 | 2019-2025 | Trelegy Ellipta |
| Allergan, INC. | $63.69 | 2019-2020 | |
| Pfizer INC. | $56.92 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $56.40 | 2021-2023 | |
| Impel Pharmaceuticals INC. | $47.70 | 2022-2023 | Trudhesa |
| Shield Therapeutics INC | $46.31 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $28.57 | 2021 | |
| Aimmune Therapeutics, INC. | $28.33 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.55 | 2021 | |
| Vivus LLC | $20.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.60 | 2019 | |
| Currax Pharmaceuticals LLC | $18.17 | 2019 | |
| Merck Sharp & Dohme LLC | $15.12 | 2019 | |
| Medicure Pharma INC. | $14.25 | 2024 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Stolyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.